Ocugen licenses OCU400 retinitis pigmentosa gene therapy rights to Roots Pharmaceutical in MENA region
Ocugen signed an exclusive MENA licensing deal with Roots Pharmaceutical for OCU400, its modifier gene therapy for retinitis pigmentosa. Terms include an upfront license fee, up to $4 million in initial development payments, up to $255 million in sales milestones. Ocugen will earn 22% royalties on OCU400 net sales in t